AZNAstraZenecaSigning up patients
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
High-risk Muscle Invasive Urothelial Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 915 (planned)
- Started
- Jul 16, 2026
- Main results expected
- Sep 11, 2030
- Fully finished
- Nov 23, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of disease-free survival (DFS) (based on Investigator assessments).
Measured over: From randomisation until disease recurrence as assessed by investigator or death due to any cause (anticipated to be up to 49 months after the first subject in).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07720284 · record last updated 2026-07-22 · checked 2026-11-09 15:47 UTC